Royalty & Structured Life-Sciences Financings

A royalty financing turns a future revenue stream, typically royalties on an approved drug, biologic, or device, into capital today. The holder of the royalty sells all or part of it to a buyer for an upfront payment, or borrows against it, while the underlying product keeps selling. It lets developers, universities, and inventors monetize an asset without issuing equity or giving up the program, and it gives investors exposure to a defined cash flow rather than to a whole company.

In a true monetization, the seller already owns a royalty, usually under a license, and sells that existing entitlement. In a synthetic royalty, no royalty exists yet. The developer agrees to pay an investor a percentage of future product revenue in exchange for funding, which creates the royalty by contract. The two are documented differently and raise different questions on assignment, security, and what happens if the product underperforms, so the structure has to match which one a deal actually is.

By taking collateral that exists before the revenue does. The investor takes a security interest in the patents, the regulatory filings and the license, perfected by a UCC filing in the state where the developer is organized; recording the lien at the Patent and Trademark Office does not perfect it, but it protects the lender against a later bona fide purchaser of the patent, so both are done. The funding is tranched to the file, with later draws conditioned on FDA acceptance, approval or first commercial sale, and the agreement states what a complete response letter triggers, usually a standstill on further draws rather than an event of default. The investor's remedy if the product never clears is the collateral and a negotiated right to the program's other revenues, which is why the covenant package reads like a term loan even when the instrument is called a royalty.

On the capital side, royalty funds, credit funds, and other institutional investors that want defined, product-linked cash flows. On the other side, pharmaceutical and biotech developers, medical-device companies, universities and research institutions, and individual inventors who hold a royalty or a program and need funding without diluting equity. We act for buyers and lenders as well as sellers and developers, and we structure each deal to the party we represent.

Yes, and the two run on different clocks. Patent protection is twenty years from the earliest non-provisional filing date, which for a drug approved a decade into development leaves ten or so years of market life unless a Hatch-Waxman extension adds back up to five. Regulatory exclusivity runs from approval and does not depend on patents at all: five years for a new chemical entity, seven for an orphan designation, twelve for a reference biologic, with six months added to each for completed pediatric studies. A royalty buyer models the stream to the later of the two and then discounts for the Paragraph IV challenge that can arrive four years after approval. The license adds a third clock of its own, since many royalty terms run until the later of patent expiry or a fixed period after first commercial sale, country by country.

By treating the royalty as several national assets rather than one. A European patent becomes a bundle of national patents on grant, and since 2023 many of them can be enforced or revoked in a single action at the Unified Patent Court, so a royalty on European sales rests on several registers and one new forum. The right to be paid is governed by the law of the license: under English law the licensee may go on paying the seller with a good discharge until it receives written notice of the assignment, so the notice letter is a closing deliverable rather than an afterthought. Withholding tax is checked in each paying country against the treaty with the buyer's domicile. We hold the structure and the financing documents, our partner firms in London and Dubai cover their jurisdictions, and locally admitted counsel is brought in where the licensee or the patents sit elsewhere.